At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 106 enrolled
Drug / intervention
DCV +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection
In Brief
A Phase 3 clinical trial evaluating DCV, SOF, and 1 other intervention for Hepatitis C. Completed, enrolled 106 participants across 19 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2016
Primary CompletionMar 2017
Study CompletionMay 2017
TodayJul 2026
First PostedFeb 4, 2016
Enrollment StartMar 15, 2016
Primary CompletionMar 2, 2017
Study CompletionMay 26, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.4 years ago
Interventions
DCVdrug
SOFdrug
RBVdrug